Nuveen Asset Management, LLC Uni Qure N.V. Transaction History

Nuveen Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$11.12 - $22.2 $17,258 - $34,454	1,552 Added 3.02%	52,988 $607,000
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $66,104 - $81,552	3,535 Added 7.38%	51,436 $1.04 Million
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $22,070 - $33,275	1,218 Added 2.61%	47,901 $1.09 Million
Q3 2022 Nov 14, 2022	SELL	$16.98 - $25.54 $11,801 - $17,750	-695 Reduced 1.47%	46,683 $876,000
Q2 2022 Aug 15, 2022	BUY	$13.15 - $20.45 $151,632 - $235,808	11,531 Added 32.17%	47,378 $883,000
Q1 2022 May 16, 2022	BUY	$14.54 - $21.5 $72,220 - $106,790	4,967 Added 16.08%	35,847 $620,000
Q4 2021 Feb 14, 2022	SELL	$20.24 - $36.01 $86,930 - $154,662	-4,295 Reduced 12.21%	30,880 $640,000
Q3 2021 Nov 12, 2021	BUY	$26.01 - $38.22 $914,901 - $1.34 Million	35,175 New	35,175 $1.13 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.